SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1970 mL オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1970 ml

fresenius kabi australia pty ltd - fish oil - rich in omega-3 acids, quantity: 30 g/l; soya oil, quantity: 60 g/l; olive oil, quantity: 50 g/l; medium chain triglycerides, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; sodium oleate; egg lecithin; glycerol; water for injections; dl-alpha-tocopherol - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1477 mL オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1477 ml

fresenius kabi australia pty ltd - olive oil, quantity: 50 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; medium chain triglycerides, quantity: 60 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: water for injections; dl-alpha-tocopherol; sodium oleate; sodium hydroxide; egg lecithin; glycerol - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN ELECTROLYTE FREE amino acids 5.1% / lipids 3.8% / glucose 12.7% emulsion for intravenous infusion bag 986 mL オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

smofkabiven electrolyte free amino acids 5.1% / lipids 3.8% / glucose 12.7% emulsion for intravenous infusion bag 986 ml

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l; olive oil, quantity: 50 g/l; soya oil, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: dl-alpha-tocopherol; water for injections; sodium hydroxide; egg lecithin; glycerol; sodium oleate - parenteral nutrition for adult patients when oral or enteral nutrition is impossible, insufficient or contraindicated.

SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 986 mL オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 986 ml

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; soya oil, quantity: 60 g/l; olive oil, quantity: 50 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; egg lecithin; sodium hydroxide; glycerol; dl-alpha-tocopherol; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

SODIUM PHENYLACETATE AND SODIUM BENZOATE injection, solution, concentrate アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

sodium phenylacetate and sodium benzoate injection, solution, concentrate

ailex pharmaceuticals, llc - sodium phenylacetate (unii: 48n6u1781g) (phenylacetic acid - unii:er5i1w795a), sodium benzoate (unii: oj245fe5eu) (benzoic acid - unii:8skn0b0mim) - sodium phenylacetate 100 mg in 1 ml - sodium phenylacetate and sodium benzoate injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. during acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see warnings and precautions (5) ]. none. pregnancy category c. animal reproduction studies have not been conducted with sodium phenylacetate and sodium benzoate injection, 10%/10%. it is not known whether sodium phenylacetate and sodium benzoate injection, 10%/10% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. thus, sodium phenylacetate and sodium benzoate injection, 10%/10% should be given to a pregnant woman only if clearly needed. it is not known whether sodium phenylacetate, sodium benzoate, or their conjugation p

ACETAMINOPHEN AND CODEINE PHOSPHATE solution アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

acetaminophen and codeine phosphate solution

nucare pharmaceuticals,inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - acetaminophen 120 mg in 5 ml - acetaminophen and codeine phosphate oral solution is indicated for the management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen and codeine phosphate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia acetaminophen and codeine phosphate oral solution is contraindicated for: - all children younger than 12 years of age [see warnings ]. - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see warnings ].  acetaminophen and codeine phos

Jalupro HMW Dermal Biorevitalizer イタリア - 英語 - myHealthbox

jalupro hmw dermal biorevitalizer

professional derma - amino acids, sodium hyaluronate - injectable solution

Jalupro Masks イタリア - 英語 - myHealthbox

jalupro masks

professional derma - amino acids, sodium hyaluronate - face, neck decolletè, eye masks

PHEBURANE sodium phenylbutyrate 483 mg/g granule bottle オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pheburane sodium phenylbutyrate 483 mg/g granule bottle

orpharma pty ltd - sodium phenylbutyrate, quantity: 483 mg/g - granules - excipient ingredients: povidone; ethylcellulose; hypromellose; macrogol 1500; sucrose; hydrolysed maize starch - pheburane (sodium phenylbutyrate) is indicated for the management of hyperammonaemia associated with urea cycle disorders. pheburane? should be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, and protein-free calorie supplements)

ACETAMINOPHEN AND CODEINE PHOSPHATE tablet アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

acetaminophen and codeine phosphate tablet

redpharm drug, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - acetaminophen 300 mg - acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain,where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings], reserve acetaminophen and codeine phosphate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] have not provided adequate analgesia, or are not expected to provide adequate analgesia have not been tolerated, or are not expected to be tolerated acetaminophen and codeine phosphate tablets are contraindicated in patients with: patients with significant respiratory depression [see warnings]. patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings]. postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy [see warni